Project Grant R34HL177243
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $538,998 Project Grant to Texas A&M AgriLife Research under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The 4-year "Deep in the Heart" project aims to develop and evaluate a community-engaged intervention to prevent obesity and cardiovascular disease risk factors in rural South Texas women. The project will involve formative research, a multilevel intervention including group classes, a...
- This $185,760 Project Grant was awarded on August 25, 2025 by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) to Oregon Health & Science University. The grant aims to support the development of the necessary skills and training for the applicant to lead the advancement of cardiovascular disease (CVD) risk assessment for women. The key research objectives are to: 1) test sex-differences in the predictive performance of existing...
- The National Heart, Lung, and Blood Institute (NHLBI), which is part of the National Institutes of Health (NIH), awarded a $688,525 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of California, San Diego (UCSD). The grant, titled "Blood Pressure Control Advancing Refugee Health Equity (BPCARE): An RCT of Adherence", aims to develop and test a behavioral intervention to improve antihypertensive medication adherence and blood pressure...
- The George Washington University received a $178,367 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) for the "SUPPORT YOUR HEART: FEASIBILITY TRIAL OF A CARDIOVASCULAR HEALTH INTERVENTION FOR YOUNG ADULTS" project. This 2-year feasibility study aims to develop and evaluate a telephone-delivered health coaching intervention for young adults targeting the American Heart Association's "Life's Essential 8"...
- This Project Grant award from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research program (CFDA 93.837), provides $696,945 to the University of North Carolina at Chapel Hill to investigate the crossover effects of adolescent stress on parent cardiovascular health. The research aims to identify how adolescent daily stressors can affect parental cardiometabolic risk and inflammation, two key risk factors for cardiovascular disease (CVD). The 5-year project...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $763,858 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Brigham & Women's Hospital Inc. (a subsidiary of Partners Healthcare System Inc.) to assess the impact of improving cardiovascular disease (CVD) care for adults with diagnosed diabetes across diverse global settings. The project, led by Dr. Jennifer Manne-Goehler and an interdisciplinary team, aims to develop the PREDICT-DM global...
- This $100,998 project grant awarded by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to The Regents of the University of California, San Francisco (UCSF) aims to evaluate the effects of universal pre-kindergarten (pre-K) access policies on the cardiovascular health of approximately 28 million parents of young children in the United States. The study will leverage the National Health Interview Survey to examine how parenthood, universal pre-K, and...
- The National Heart, Lung, and Blood Institute (NHLBI), through its Cardiovascular Diseases Research federal grant program (CFDA 93.837), awarded a $169,992 Project Grant to the University of Colorado-Denver on September 18, 2025. The grant will fund a 5-year mixed methods study to inform initial antihypertensive prescribing and develop a patient self-titration intervention. The study aims to understand barriers and facilitators to initiating antihypertensive combination therapy versus stepped...
- The National Heart, Lung, and Blood Institute (NHLBI) has awarded a $126,309 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Children's Hospital Medical Center in Cincinnati, Ohio. This 2-year research project, awarded on June 16, 2025, aims to characterize the functional role of a novel cardiac and adipose-enriched microprotein called NRAC and its involvement in lipid droplet biogenesis and lipid metabolism within the cardiovascular system. The research will...
- The National Institutes of Health's National Heart, Lung and Blood Institute awarded $2,350,623 under the Cardiovascular Diseases Research program (CFDA 93.837) to the Regents of the University of Minnesota on May 1, 2021 for a project concluding on April 30, 2022. The project aims to reduce childhood obesity through an individual randomized controlled trial testing combinations of ecological momentary intervention, home visiting, and video feedback delivered to 510 low-income, racially...
The National Heart Lung and Blood Institute (NHLBI), under CFDA 93.837 Cardiovascular Diseases Research, awarded a 3-year, $197,160 Project Grant to Oregon Health & Science University (OHSU) to determine the feasibility, acceptability, and initial effect of the Rural Caregiver Heart Health Education (RICHH) intervention for cardiovascular disease (CVD) risk reduction in custodial grandparents. The RICHH intervention, originally targeted for adult caregivers of chronically ill family members, has not been tested with custodial grandparents who face unique health risks. Through a 2-arm randomized controlled trial with 70 custodial grandparents in Oregon, this project aims to assess the virtual delivery of the RICHH intervention in optimizing healthy aging and cardiovascular health in this growing at-risk population. The grant period runs from August 1, 2025 to July 31, 2028.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $197.2k | 7/31/25 |